Mathematics of Computation

American Mathematical Society
American Mathematical Society
ISSN: 00255718, 10886842

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q1
WOS
Q1
Impact factor
2.2
SJR
1.460
CiteScore
3.9
Categories
Algebra and Number Theory
Applied Mathematics
Computational Mathematics
Areas
Mathematics
Years of issue
1864, 1926, 1943-2025
journal names
Mathematics of Computation
MATH COMPUT
Publications
11 179
Citations
183 864
h-index
155
Top-3 citing journals
Top-3 organizations
University of Minnesota
University of Minnesota (66 publications)
Texas A&M University
Texas A&M University (58 publications)
University of New South Wales
University of New South Wales (52 publications)
Top-3 countries
USA (1166 publications)
Germany (466 publications)
France (359 publications)

Most cited in 5 years

Found 
from chars
Publications found: 747
Detailed investigation of the levodopa response rates in distinct motor subscores in Parkinson’s disease patients with and without STN-DBS
Onder H., Oksuz M., Comoglu S.
Q2
Taylor & Francis
Neurodegenerative disease management 2025 citations by CoLab: 0
Correction
Q2
Taylor & Francis
Neurodegenerative disease management 2025 citations by CoLab: 0
Economic evaluation of mHealth solutions in PD: where do we stand?
Kanellos F.S., Petkou E., Konitsiotis S., Simos Y.V., Lakkas L., Peschos D., Tsamis K.I.
Q2
Taylor & Francis
Neurodegenerative disease management 2025 citations by CoLab: 0
Advances in the management of Alzheimer’s disease
Faheem M.S., Khan A.A., Nawaz M.
Q2
Taylor & Francis
Neurodegenerative disease management 2025 citations by CoLab: 0
A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?
Barrett A., Olayinka-Amao O., Ziemssen T., Bharadia T., Henke C., Kamudoni P.
Q2
Taylor & Francis
Neurodegenerative disease management 2025 citations by CoLab: 0
Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice
Amin M., Harvey T., Pineda D.M., Tai M., Shao Q., Brown B., Gadkari A., Moss B., Conway D.S., Hersh C.M.
Q2
Taylor & Francis
Neurodegenerative disease management 2025 citations by CoLab: 0
Friedreich ataxia: what can we learn from non-GAA repeat mutations?
Lynch D.R., Shen M., Wilson R.B.
Q2
Taylor & Francis
Neurodegenerative disease management 2025 citations by CoLab: 0
Gut microbiota and multiple sclerosis: a potential diagnostic and prognostic marker?
Zoledziewska M., Lorefice L.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 0
Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies
A Virata M.C., Catahay J.A., Lippi G., Henry B.M.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 0
An interdisciplinary approach to rehabilitation in Parkinson's disease: case series
Lowell E.R., Macpherson C., Villarreal-Cavazos K., Chandrana A., Sevitz J.S., Veit K., Dakin A., Quinn L., Troche M.S.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 0
Effectiveness of neuro-feedback on Alzheimer’s rehabilitation: a bibliometric analysis
Verma S., Kurdekar A.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 0
Biological activities of astaxanthin in the treatment of neurodegenerative diseases
Lotfi A., Abroodi Z., Khazaei M.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 1
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary
Brochet B., Solari A., Lechner-Scott J., Piehl F., Langdon D., Hupperts R., Selmaj K., Patti F., Brieva L., Maidal E.M., Alexandri N., Smyk A., Nolting A., Montalban X., Kubala Havrdova E.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 0
Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care
Rutherford H.A., Rush B.K., Smith A., Sullivan E., Martinez-Rubio C., Toumadj A., Piana R.L., Cassandro C.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 0
Benefits of self-paced concurrent training on lung function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis
Jallouli S., Maaloul R., Ghroubi S., Kammoun R., Damak M., Sakka S., Driss T., Marco G.D., Mhiri C., Elleuch M.H., Feki W., Hammouda O.
Q2
Taylor & Francis
Neurodegenerative disease management 2024 citations by CoLab: 0

Top-100

Citing journals

1000
2000
3000
4000
5000
6000
7000
Show all (70 more)
1000
2000
3000
4000
5000
6000
7000

Citing publishers

10000
20000
30000
40000
50000
60000
Show all (70 more)
10000
20000
30000
40000
50000
60000

Publishing organizations

10
20
30
40
50
60
70
Show all (70 more)
10
20
30
40
50
60
70

Publishing organizations in 5 years

1
2
3
4
5
6
7
8
9
Show all (70 more)
1
2
3
4
5
6
7
8
9

Publishing countries

200
400
600
800
1000
1200
USA, 1166, 10.43%
Germany, 466, 4.17%
France, 359, 3.21%
China, 351, 3.14%
Canada, 219, 1.96%
United Kingdom, 218, 1.95%
Spain, 148, 1.32%
Australia, 138, 1.23%
Italy, 131, 1.17%
Netherlands, 95, 0.85%
Japan, 89, 0.8%
Switzerland, 87, 0.78%
Austria, 83, 0.74%
Norway, 65, 0.58%
Sweden, 51, 0.46%
Chile, 49, 0.44%
Belgium, 47, 0.42%
Israel, 43, 0.38%
Poland, 43, 0.38%
Greece, 41, 0.37%
Singapore, 38, 0.34%
Russia, 37, 0.33%
Republic of Korea, 37, 0.33%
Brazil, 32, 0.29%
Argentina, 29, 0.26%
Ireland, 28, 0.25%
Hungary, 26, 0.23%
Finland, 26, 0.23%
India, 23, 0.21%
Mexico, 21, 0.19%
New Zealand, 21, 0.19%
Czech Republic, 16, 0.14%
Serbia, 13, 0.12%
Portugal, 12, 0.11%
South Africa, 12, 0.11%
Denmark, 11, 0.1%
Saudi Arabia, 11, 0.1%
Turkey, 10, 0.09%
Bulgaria, 9, 0.08%
Croatia, 8, 0.07%
Romania, 7, 0.06%
Slovenia, 7, 0.06%
Algeria, 6, 0.05%
Egypt, 6, 0.05%
Lebanon, 5, 0.04%
Lithuania, 5, 0.04%
Ukraine, 4, 0.04%
Bosnia and Herzegovina, 4, 0.04%
Venezuela, 4, 0.04%
Iran, 4, 0.04%
Cyprus, 4, 0.04%
Virgin Islands, U.S., 3, 0.03%
Iraq, 3, 0.03%
Iceland, 3, 0.03%
Kuwait, 3, 0.03%
Oman, 3, 0.03%
Kazakhstan, 2, 0.02%
Estonia, 2, 0.02%
Armenia, 2, 0.02%
Brunei, 2, 0.02%
Vietnam, 2, 0.02%
Georgia, 2, 0.02%
Colombia, 2, 0.02%
Morocco, 2, 0.02%
UAE, 2, 0.02%
Slovakia, 2, 0.02%
Tunisia, 2, 0.02%
Bahrain, 1, 0.01%
Botswana, 1, 0.01%
Luxembourg, 1, 0.01%
Pakistan, 1, 0.01%
Puerto Rico, 1, 0.01%
Uruguay, 1, 0.01%
Philippines, 1, 0.01%
French Polynesia, 1, 0.01%
Montenegro, 1, 0.01%
Yugoslavia, 1, 0.01%
Show all (47 more)
200
400
600
800
1000
1200

Publishing countries in 5 years

10
20
30
40
50
60
70
80
90
USA, 85, 16.19%
China, 54, 10.29%
Germany, 50, 9.52%
France, 37, 7.05%
United Kingdom, 26, 4.95%
Austria, 19, 3.62%
Australia, 15, 2.86%
Canada, 15, 2.86%
Italy, 14, 2.67%
Switzerland, 11, 2.1%
Belgium, 9, 1.71%
Netherlands, 8, 1.52%
Singapore, 8, 1.52%
Norway, 6, 1.14%
Spain, 5, 0.95%
Argentina, 4, 0.76%
Brazil, 4, 0.76%
Poland, 4, 0.76%
Sweden, 4, 0.76%
Greece, 3, 0.57%
Denmark, 3, 0.57%
Israel, 3, 0.57%
Finland, 3, 0.57%
Czech Republic, 3, 0.57%
Chile, 3, 0.57%
Japan, 3, 0.57%
Russia, 2, 0.38%
Portugal, 2, 0.38%
Bosnia and Herzegovina, 2, 0.38%
India, 2, 0.38%
Saudi Arabia, 2, 0.38%
Slovenia, 2, 0.38%
Bulgaria, 1, 0.19%
Egypt, 1, 0.19%
Ireland, 1, 0.19%
Iceland, 1, 0.19%
Lebanon, 1, 0.19%
Luxembourg, 1, 0.19%
Mexico, 1, 0.19%
UAE, 1, 0.19%
Republic of Korea, 1, 0.19%
Serbia, 1, 0.19%
Croatia, 1, 0.19%
Show all (13 more)
10
20
30
40
50
60
70
80
90